Advertisement
Anesthesiology and Pulmonary Medicine
Subscribe to Anesthesiology and Pulmonary Medicine
View Sample

FREE Email Newsletter

Masimo to Present at the Roth Growth Stock Conference

March 3, 2011 6:35 am | by Bio-Medicine.Org | News | Comments

IRVINE, Calif., March 3, 2011 /- Masimo (Nasdaq: MASI ) today announced that its management is scheduled to present at the Roth 23rd Annual Growth Stock Conference at the Ritz-Carlton in Laguna Niguel, Calif. on Tuesday, March 15, 2011, at 9:00 a.m. P.T.  A live audiocast of the...

Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTAâ„¢

March 3, 2011 4:37 am | by Bio-Medicine.Org | News | Comments

CHAPEL HILL, N.C., March 3, 2011 /- Cempra Pharmaceuticals today announced the appointment of David Oldach, M.D. as vice president, clinical research as well as announcing an expansion of its clinical development team to manage the company's leading clinical programs, solithromycin and...

Insmed Announces European Medicines Agency Acceptance of Its Pediatric Investigation Plan for ARIKACEâ„¢ in the Cystic Fibrosis Pseudomonas Indication

March 3, 2011 4:36 am | by Bio-Medicine.Org | News | Comments

RICHMOND, Va., March 3, 2011 /- Insmed Incorporated (Nasdaq: INSM ), a biopharmaceutical company, announced today that the Pediatric Committee of the European Medicines Agency (EMA) has issued a positive opinion on the Company's Pediatric Investigation Plan (PIP) for ARIKACE™...

Advertisement

Ventus Medical Receives CE Mark for Provent® Sleep Apnea Therapy

March 3, 2011 4:36 am | by Bio-Medicine.Org | News | Comments

BELMONT, Calif., March 3, 2011 /- Ventus Medical, Inc. a privately-held medical device company dedicated to providing novel products to treat sleep-disordered breathing, today announced that it has received CE Mark for its Provent® Sleep Apnea Therapy. (Photo:  ...

Dehaier Medical to Report Fourth Quarter and Full-Year 2010 Financial Results on March 7

March 3, 2011 4:36 am | by Bio-Medicine.Org | News | Comments

BEIJING, March 3, 2011 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (Nasdaq: DHRM ) ("Dehaier" or the "Company"), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that it will...

Ikaria® to Present at 31st Annual Cowen and Company Healthcare Conference

March 2, 2011 6:35 am | by Bio-Medicine.Org | News | Comments

CLINTON, N.J., March 2, 2011 /- Ikaria, Inc. today announced that its Chairman and CEO, Daniel Tasse, will present at the 31st Annual Cowen and Company Healthcare Conference on Wednesday, March 9, 2011 at 8:30 a.m. EST.  The conference will be held March 7-9 at the Boston Marriott...

N30 Pharmaceuticals to Present S-Nitrosoglutathione Reductase Inhibitor Preclinical Safety Data at 2011 Society of Toxicology 50th Anniversary Meeting

March 2, 2011 1:34 am | by Bio-Medicine.Org | News | Comments

BOULDER, Colo., March 2, 2011 /- N30 Pharmaceuticals, LLC (N30 Pharma) today announced it will present data at the 2011 Annual Meeting of the Society of Toxicology in Washington, D.C. on Monday, March 7, 2011. The data describe the preclinical safety evaluation of small molecule...

An Easier Way to Breathe Better - ICAP Ocean Tomo Announces an Advanced Medical Inhaler Design

March 1, 2011 9:34 am | by Bio-Medicine.Org | News | Comments

CHICAGO, March 1, 2011 /- Developed by inventor John Vito and represented by ICAP Ocean Tomo , the assets available for auction in this lot disclose an advanced medical inhaler design that is both more accurate and more convenient for the user. (Logo:  ...

Advertisement

UPDATE: FDA Approves New Drug to Treat Chronic Obstructive Pulmonary Disease

March 1, 2011 9:34 am | by Bio-Medicine.Org | News | Comments

SILVER SPRING, Md., March 1, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration approved roflumilast, a pill taken daily to decrease the frequency of flare-ups (exacerbations) or worsening of symptoms from severe chronic obstructive pulmonary disease (COPD). (Logo:...

Insmed Shareholders Approve Conversion of Series B Conditional Convertible Preferred Stock and Reverse Stock Split

March 1, 2011 6:35 am | by Bio-Medicine.Org | News | Comments

RICHMOND, Va., March 1, 2011 /- Insmed Incorporated (Nasdaq: INSM ), a biopharmaceutical company, announced today that Insmed's shareholders approved the proposal relating to the conversion of Insmed's Series B Conditional Convertible Preferred Stock (Series B Preferred Stock) into...

FDA Approves New Drug to Treat Chronic Obstructive Pulmonary Disease

March 1, 2011 6:35 am | by Bio-Medicine.Org | News | Comments

SILVER SPRING, Md., March 1, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration approved roflumilast, a pill taken daily to decrease the frequency of flare-ups (exacerbations) or worsening of symptoms from severe chronic obstructive pulmonary disease (COPD). (Logo:...

Dehaier Medical Announces March Investor Presentations

March 1, 2011 2:35 am | by Bio-Medicine.Org | News | Comments

BEIJING, March 1, 2011 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (Nasdaq: DHRM ) ("Dehaier" or the "Company"), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that management...

Study finds close linkage between a rare, deadly lung condition and blood cell abnormalities

February 28, 2011 4:34 pm | by EurekAlert | News | Comments

(American Society of Hematology) Results from a study published in Blood, the journal of the American Society of Hematology, reveal a close relationship between pulmonary arterial hypertension -- exceedingly high blood pressure in the arteries carrying blood from the heart to the lungs --...

Advertisement

OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference

February 28, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

BOTHELL, Wash., and VANCOUVER, British Columbia, Feb. 28, 2011 /- OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI ) announced today that Scott Cormack, OncoGenex's president and chief executive officer, will take part in a panel discussion on novel cancer treatments at the upcoming RBC...

Fish oil fights weight loss due to chemotherapy

February 27, 2011 8:32 pm | by EurekAlert | News | Comments

(Wiley-Blackwell) A new analysis has found that supplementing the diet with fish oil may prevent muscle and weight loss that commonly occurs in cancer patients who undergo chemotherapy. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study...

Radio-guided surgery a safe and simple way to remove potentially cancerous nodules in the lung

February 25, 2011 10:33 pm | by EurekAlert | News | Comments

(European Society for Medical Oncology) Using tiny spheres of radioactive liquid to guide surgeons as they remove potentially cancerous material in the lungs is safe and more effective than other techniques, Italian researchers report.

Erlotinib effective and with fewer side-effects after first-line treatment

February 25, 2011 10:33 pm | by EurekAlert | News | Comments

(European Society for Medical Oncology) The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated, in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy, the results of a new phase III trial show.

ERT to Present at the Citi 2011 Global Health Care Conference on March 2, 2011

February 25, 2011 7:34 am | by Bio-Medicine.Org | News | Comments

PHILADELPHIA, Feb. 25, 2011 /- ERT (Nasdaq: ERES ), announced today that Dr. Joel Morganroth, the Company's Chairman and CEO, and Keith Schneck, the Company's Chief Financial Officer, are scheduled to present at the Citi 2011 Global Health Care Conference at 10:00 AM ET on March 2,...

Seniors in Florida Report Problems Obtaining Needed Home Medical Equipment and Services Under Controversial Medicare Bidding System

February 25, 2011 7:34 am | by Bio-Medicine.Org | News | Comments

ORLANDO, Fla., Feb. 25, 2011 /PRNewswire-USNewswire/ -- Medicare beneficiaries are reporting problems receiving required home medical equipment and services in the wake of the January 1, 2011 implementation of Medicare's controversial "competitive" bidding program in Miami and Orlando,...

Bone drug zoledronic acid may help prevent spread of early lung cancer

February 24, 2011 10:33 pm | by EurekAlert | News | Comments

(European Society for Medical Oncology) A drug that is currently used to help treat bone metastases in patients with lung cancer could also be useful at an earlier stage of treatment, to prevent the cancer from spreading in the first place, Italian researchers have found.

Vertex sees positive data from Phase 3 CF study

February 23, 2011 9:33 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Vertex Pharmaceuticals Inc. of Cambridge today released results of a Phase 3 study of its VX-770 drug candidate for a specific type of cystic fibrosis (CF) that showed a relative mean improvement in lung function of about 17 percent over placebo.

European Multidisciplinary Conference in Thoracic Oncology -- press program

February 23, 2011 5:35 am | by EurekAlert | News | Comments

(European Society for Medical Oncology) The following studies will be presented in the Press Program of the second European Multidisciplinary Conference in Thoracic Oncology, a multipartner initiative for physicians of all medical disciplines dealing with lung cancer and other thoracic malignancies.

Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation

February 23, 2011 5:35 am | by Bio-Medicine.Org | News | Comments

BETHESDA, Md., Feb. 23, 2011 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation and Vertex Pharmaceuticals announced today that VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis, showed promising results in a Phase 3 clinical...

Insmed to Host Fourth Quarter and 2010 Year-End Earnings Conference Call

February 23, 2011 3:33 am | by Bio-Medicine.Org | News | Comments

RICHMOND, Va., Feb. 23, 2011 /- Insmed Incorporated (Nasdaq: INSM ), a biopharmaceutical company, announced today that it will host a conference call on Thursday, March 10th, 2011, at 8:30 AM EST, to discuss its financial results for the fourth quarter and year-end 2010.  Insmed...

Reportlinker Adds Global Artificial Organs Industry

February 23, 2011 2:36 am | by Bio-Medicine.Org | News | Comments

NEW YORK, Feb. 23, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Global Artificial Organs Industry http://www.reportlinker.com/p092544/Global-Artificial-Organs-Industry.html This report analyzes the worldwide markets for Artificial...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading